A 32-year-old man with newly diagnosed HIV-1 infection (CD4 count 350 cells/μL, viral load 150,000 copies/mL) presents to the antiretroviral clinic. He has no prior antiretroviral exposure and no contraindications to standard therapy. Which of the following is the preferred first-line integrase strand transfer inhibitor (INSTI)-based regimen in India?